AREDS 2 is a multi-center randomized trial of 4,000 participants designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs (DHA and EPA) on the progression to advanced AMD. The study will enroll participants aged 50 to 85 years, with sufficiently clear ocular media to allow accurate assessment of AMD from fundus photographs. Participants should have either bilateral large drusen (>125 microns) or large drusen in one eye and advanced AMD in the fellow eye. All participants will be offered additional treatment with the original AREDS formulation (now considered standard of care) and 3 variations of this formula. These are: (1) no beta-carotene;(2) lower amounts of zinc;and (3) no beta-carotene and lower amounts of zinc. Eligible participants will be followed for a minimum of five years.

Agency
National Institute of Health (NIH)
Type
Research and Development Contracts (N01)
Project #
N01EY60003-11-0-1
Application #
8740462
Study Section
Project Start
2006-04-01
Project End
2014-03-31
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$749,640
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715